Boston Molecules has finalized the configuration of its ZyaltTM COVID-19 IgM&IgG DR TEST kit, and will commence scaled up production as soon as the FDA Emergency Use Authorization (EUA) is granted. The DR (double rapid) TEST device employs a simple, easy-to-use method to detect the presence of human IgG and IgM antibodies in blood, plasma or serum samples, which could reveal the history of SARS-CoV-2 exposure. Boston Molecules has been granted manufacturer operator number 10070123 and registration number 3016734013 by FDA for this device. Tests on clinical samples (212 in total) show 96% PPA (positive percent agreement) and 100% NPA (negative percent agreement) with nucleic acid qPCR tests. Boston Molecules has provided test kits to Fulgent Genetics Inc., California for further clinical trials, and to rule out cross-reactivity with antibodies resulting from previous infections by other types of coronavirus. A highly automated robotic production line aimed at the monthly production of millions of test kits is on Boston Molecules’ agenda.

Boston Molecules developed a novel mammalian protein platform (Z-ActiveTM) using chaperone-assisted protein expression technology to express super active cytokines and growth factors. The average protein activity is about 5-10 fold higher than competitors (R&D system, Pepro Tech. et al.) SERVICE FEATURES From gene to protein Gene synthesis Cloning Transformation Expression & purification From E.coli to mammalian E.coli Yeast Insect Mammalian High purity >97% SDS Low endotoxin <0.10 EU per 1 μg of the protein Quotations: Get an instant quote

Boston MoleculesTM is a leading custom antibody developer facilitated with cutting edge technologies and innovations. Our B-cell cloning antibody platform is emerging as the world’s best monoclonal antibody development strategy that outperformed traditional hybridoma technologies by more than 10 fold increase of positive colony numbers and superior affinities in selected antibodies. Cohesive with our Bioinformatics scientists and Crystallography scientists, our custom antibody services deliver >90% successful projects by guaranteed antibody development strategies including antigen 3D structure prediction and homologous sequence exclusions. We also offer 60-70 days short turnaround cost-efficient polyclonal antibody services with free epitobe prediction service. SERVICE FEATURES Cutting edge B-Cell cloning technologies >95% successful rate Guaranteed packages Western blot guaranteed packages Elisa guaranteed packages IHC guaranteed packages IP guaranteed packages Fast turnaround (60-70 days delivery of polyclonal antibody) Quotations: Get an instant quote

Boston MoleculesTM is a leading custom antibody developer facilitated with cutting edge technologies and innovations. Our B-cell cloning antibody platform is emerging as the world’s best monoclonal antibody development strategy that outperformed traditional hybridoma technologies by more than 10 fold increase of positive colony numbers and superior affinities in selected antibodies. Cohesive with our Bioinformatics scientists and Crystallography scientists, our custom antibody services deliver >90% successful projects by guaranteed antibody development strategies including antigen 3D structure prediction and homologous sequence exclusions. We also offer 60-70 days short turnaround cost-efficient polyclonal antibody services with free epitobe prediction service. SERVICE FEATURES Cutting edge B-Cell cloning technologies >95% successful rate Guaranteed packages Western blot guaranteed packages Elisa guaranteed packages IHC guaranteed packages IP guaranteed packages Fast turnaround (60-70 days delivery of polyclonal antibody) Quotations: Get an instant quote

Boston Molecules developed a novel mammalian protein platform (Z-ActiveTM) using chaperone-assisted protein expression technology to express super active cytokines and growth factors. The average protein activity is about 5-10 fold higher than competitors (R&D system, Pepro Tech. et al.) SERVICE FEATURES From gene to protein Gene synthesis Cloning Transformation Expression & purification From E.coli to mammalian E.coli Yeast Insect Mammalian High purity >97% SDS Low endotoxin <0.10 EU per 1 μg of the protein Quotations: Get an instant quote

Boston Molecules has finalized the configuration of its ZyaltTM COVID-19 IgM&IgG DR TEST kit, and will commence scaled up production as soon as the FDA Emergency Use Authorization (EUA) is granted. The DR (double rapid) TEST device employs a simple, easy-to-use method to detect the presence of human IgG and IgM antibodies in blood, plasma or serum samples, which could reveal the history of SARS-CoV-2 exposure. Boston Molecules has been granted manufacturer operator number 10070123 and registration number 3016734013 by FDA for this device. Tests on clinical samples (212 in total) show 96% PPA (positive percent agreement) and 100% NPA (negative percent agreement) with nucleic acid qPCR tests. Boston Molecules has provided test kits to Fulgent Genetics Inc., California for further clinical trials, and to rule out cross-reactivity with antibodies resulting from previous infections by other types of coronavirus. A highly automated robotic production line aimed at the monthly production of millions of test kits is on Boston Molecules’ agenda.